How to Paint Composite Decking | Hunker13 Jan 2011 ... composite decking is often touted as a maintenance-free alternative to lumber, yet over time its original color will fade, and some individual boards can become stained by... ... composites aren't designed to be as paintable as natural wood planks, but they can accept paint if the deck is properly cleaned, prepped and primed. A topcoat of porch paint can then restore ... with a sponge. use a scrub brush on any areas of the deck that are particularly dirty or greasy.
Which Is the Best Decking Material: Wood or Composite? | Angie's List20 Mar 2013 ... A professional deck builder explains the pros and cons of natural wood versus man-made composites for deck materials to help you estimate cost and benefits. ... Other species of wood such as redwood and hardwoods like ipe, jutoba and tigerwood are also used on decks, but not nearly as often. Manmade ... The best way to do that is to talk with a knowledgeable deck building professional that can ask you the right questions and help you make the best decision.
Planning To Stain or Paint A Deck - Tips From Sherwin-WilliamsDeck Wash use Deck Wash to remove mold and mildew from composite decking and unstained pressure-treated wood. 2. Choose the Right Stain - The type of stain you choose depends on the appearance and durability you want to achieve. Clear While offering the ... use the Right Project Materials - To properly prepare and finish your deck or porch, your project checklist should include the following items, the majority of which you'll find at your neighborhood Sherwin-Williams store:.
Should I Paint or Stain My Deck? | Angie's List24 Apr 2013 ... Thinking of painting a wood deck? Angie Hicks explains why deck builders recommend deck staining instead of painting a deck, and provides wood staining tips. ... for longevity, the best way to go, according to deck pros i've talked to, is to use a clear sealer or a semi-transparent stain on your deck. The problem with painting a deck is ... Much Does it Cost to Build a Deck? With a host of deck types and options available, what can you expect to pay for a typical job?


text:
Perversion Story - Blu-ray Premier in the US
Mondo Macabro Release with Longer European Cut
Perversion Story (OT: Una sull'altra, 1969) is an Italian thriller by Lucio Fulci. Passed away in 1994, the Italian director was quite successful with movies like Zombie aka Zombie Flesh Eaters (Zombi 2, 1979), City of the Living Dead (Paura nella città dei morti viventi, 1980) or The House by the Cemetery (Quella villa accanto al cimitero, 1981).
The thriller Perversion Story was shot 10 years prior to the huge zombie hype. On 11/18/2018, Mondo Macabro is going to release Perversion Story in the US. The Blu-ray will contain the longer "European Cut".
The extras are as follows:
HD presentation of the longer, 108 minute "European cut" of the film
English or Italian opening credits options
English or Italian with optional English subtitles language track options
BRAND NEW interview with actor Jean Sorel
BRAND NEW interview with actor Elsa Martinelli
BRAND NEW interview with critic Stephen Thrower, author of Beyond Terror: The Films of Lucio Fulci
Original trailer
Mondo Macabro previews
Buy this title on Amazon
US Blu-ray on Amazon.com
Release: Sep 15, 2018 - Author: SilentKnight - Translator: Tony Montana - Source: blu-ray.com

redpajama_set_name: RedPajamaCommonCrawl


Not to be confused with vasculogenesis.
Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels. This is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in the developing embryo form through vasculogenesis, after which angiogenesis is responsible for most, if not all, blood vessel growth during development and in disease.
Angiogenesis is a normal and vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, it is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. The essential role of angiogenesis in tumor growth was first proposed in 1971 by Judah Folkman, who described tumors as "hot and bloody."
Sprouting angiogenesis was the first identified form of angiogenesis. It occurs in several well-characterized stages. First, biological signals known as angiogenic growth factors activate receptors on endothelial cells present in pre-existing blood vessels. Second, the activated endothelial cells begin to release enzymes called proteases that degrade the basement membrane to allow endothelial cells to escape from the original (parent) vessel walls. The endothelial cells then proliferate into the surrounding matrix and form solid sprouts connecting neighboring vessels.
As sprouts extend toward the source of the angiogenic stimulus, endothelial cells migrate in tandem, using adhesion molecules called integrins. These sprouts then form loops to become a full-fledged vessel lumen as cells migrate to the site of angiogenesis. Sprouting occurs at a rate of several millimeters per day, and enables new vessels to grow across gaps in the vasculature. It is markedly different from splitting angiogenesis because it forms entirely new vessels as opposed to splitting existing vessels.
By intussusception, also known as splitting angiogenesis, a new blood vessel is created by splitting of an existing blood vessel in two.
Intussusception was first observed in neonatal rats. In this type of vessel formation, the capillary wall extends into the lumen to split a single vessel in two. There are four phases of intussusceptive angiogenesis. First, the two opposing capillary walls establish a zone of contact. Second, the endothelial cell junctions are reorganized and the vessel bilayer is perforated to allow growth factors and cells to penetrate into the lumen. Third, a core is formed between the 2 new vessels at the zone of contact that is filled with pericytes and myofibroblasts. These cells begin laying collagen fibers into the core to provide an extracellular matrix for growth of the vessel lumen. Finally, the core is fleshed out with no alterations to the basic structure. Intussusception is important because it is a reorganization of existing cells. It allows a vast increase in the number of capillaries without a corresponding increase in the number of endothelial cells. This is especially important in embryonic development as there are not enough resources to create a rich microvasculature with new cells every time a new vessel develops.
Mechanical stimulation of angiogenesis is not well characterized. There is a significant amount of controversy with regard to shear stress acting on capillaries to cause angiogenesis, although current knowledge suggests that increased muscle contractions may increase angiogenesis. This may be due to an increase in the production of nitric oxide during exercise. Nitric oxide results in vasodilation of blood vessels.
Chemical stimulation of angiogenesis is performed by various angiogenic proteins, including several growth factors.
The fibroblast growth factor (FGF) family with its prototype members FGF-1 (acidic FGF) and FGF-2 (basic FGF) consists to date of at least 22 known members. Most are single-chain peptides of 16-18 kDa and display high affinity to heparin and heparan sulfate. In general, FGFs stimulate a variety of cellular functions by binding to cell surface FGF-receptors in the presence of heparin proteoglycans. The FGF-receptor family is composed of seven members, and all the receptor proteins are single-chain receptor tyrosine kinases that become activated through autophosphorylation induced by a mechanism of FGF-mediated receptor dimerization. Receptor activation gives rise to a signal transduction cascade that leads to gene activation and diverse biological responses, including cell differentiation, proliferation, and matrix dissolution, thus initiating a process of mitogenic activity critical for the growth of endothelial cells, fibroblasts, and smooth muscle cells. FGF-1, unique among all 22 members of the FGF family, can bind to all seven FGF-receptor subtypes, making it the broadest-acting member of the FGF family, and a potent mitogen for the diverse cell types needed to mount an angiogenic response in damaged (hypoxic) tissues, where upregulation of FGF-receptors occurs. FGF-1 stimulates the proliferation and differentiation of all cell types necessary for building an arterial vessel, including endothelial cells and smooth muscle cells; this fact distinguishes FGF-1 from other pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF), which primarily drives the formation of new capillaries.
Until 2007, three human clinical trials have been successfully completed with FGF-1, in which the angiogenic protein was injected directly into the damaged heart muscle. Also, one additional human FGF-1 trial has been completed to promote wound healing in diabetics with chronic wounds.
Besides FGF-1, one of the most important functions of fibroblast growth factor-2 (FGF-2 or bFGF) is the promotion of endothelial cell proliferation and the physical organization of endothelial cells into tube-like structures, thus promoting angiogenesis. FGF-2 is a more potent angiogenic factor than VEGF or PDGF (platelet-derived growth factor); however, it is less potent than FGF-1. As well as stimulating blood vessel growth, aFGF (FGF-1) and bFGF (FGF-2) are important players in wound healing. They stimulate the proliferation of fibroblasts and endothelial cells that give rise to angiogenesis and developing granulation tissue; both increase blood supply and fill up a wound space/cavity early in the wound-healing process.
Vascular endothelial growth factor (VEGF) has been demonstrated to be a major contributor to angiogenesis, increasing the number of capillaries in a given network. Initial in vitro studies demonstrated bovine capillary endothelial cells will proliferate and show signs of tube structures upon stimulation by VEGF and bFGF, although the results were more pronounced with VEGF. Upregulation of VEGF is a major component of the physiological response to exercise and its role in angiogenesis is suspected to be a possible treatment in vascular injuries. In vitro studies clearly demonstrate that VEGF is a potent stimulator of angiogenesis because, in the presence of this growth factor, plated endothelial cells will proliferate and migrate, eventually forming tube structures resembling capillaries. VEGF causes a massive signaling cascade in endothelial cells. Binding to VEGF receptor-2 (VEGFR-2) starts a tyrosine kinase signaling cascade that stimulates the production of factors that variously stimulate vessel permeability (eNOS, producing NO), proliferation/survival (bFGF), migration (ICAMs/VCAMs/MMPs) and finally differentiation into mature blood vessels. Mechanically, VEGF is upregulated with muscle contractions as a result of increased blood flow to affected areas. The increased flow also causes a large increase in the mRNA production of VEGF receptors 1 and 2. The increase in receptor production means muscle contractions could cause upregulation of the signaling cascade relating to angiogenesis. As part of the angiogenic signaling cascade, NO is widely considered to be a major contributor to the angiogenic response because inhibition of NO significantly reduces the effects of angiogenic growth factors. However, inhibition of NO during exercise does not inhibit angiogenesis, indicating there are other factors involved in the angiogenic response.
The angiopoietins, Ang1 and Ang2, are required for the formation of mature blood vessels, as demonstrated by mouse knock out studies. Ang1 and Ang2 are protein growth factors which act by binding their receptors, Tie-1 and Tie-2; while this is somewhat controversial, it seems that cell signals are transmitted mostly by Tie-2; though some papers show physiologic signaling via Tie-1 as well. These receptors are tyrosine kinases. Thus, they can initiate cell signaling when ligand binding causes a dimerization that initiates phosphorylation on key tyrosines.
Delta-like ligand 4 (DII4) is a protein with a negative regulatory effect on angiogenesis. Dll4 is a transmembrane ligand, for the notch family of receptors.
Class 3 Semaphorins (SEMA3s) regulate angiogenesis by modulating endothelial cell adhesion, migration, proliferation, survival and the recruitment of pericytes. Furthermore, semaphorins can interfere with VEGF-mediated angiogenesis since both SEMA3s and VEGF-A compete for Neuropilin receptor binding at endothelial cells. The relative expression levels of SEMA3s and VEGF-A may therefore be important for angiogenesis.
Angiogenesis inhibitor can be endogenous or come from outside as drug or a dietary component.
Angiogenesis may be a target for combating diseases characterized by either poor vascularisation or abnormal vasculature. Application of specific compounds that may inhibit or induce the creation of new blood vessels in the body may help combat such diseases. The presence of blood vessels where there should be none may affect the mechanical properties of a tissue, increasing the likelihood of failure. The absence of blood vessels in a repairing or otherwise metabolically active tissue may inhibit repair or other essential functions. Several diseases, such as ischemic chronic wounds, are the result of failure or insufficient blood vessel formation and may be treated by a local expansion of blood vessels, thus bringing new nutrients to the site, facilitating repair. Other diseases, such as age-related macular degeneration, may be created by a local expansion of blood vessels, interfering with normal physiological processes.
The modern clinical application of the principle of angiogenesis can be divided into two main areas: anti-angiogenic therapies, which angiogenic research began with, and pro-angiogenic therapies. Whereas anti-angiogenic therapies are being employed to fight cancer and malignancies, which require an abundance of oxygen and nutrients to proliferate, pro-angiogenic therapies are being explored as options to treat cardiovascular diseases, the number one cause of death in the Western world. One of the first applications of pro-angiogenic methods in humans was a German trial using fibroblast growth factor 1 (FGF-1) for the treatment of coronary artery disease. Clinical research in therapeutic angiogenesis is ongoing for a variety of atherosclerotic diseases, like coronary heart disease, peripheral arterial disease, wound healing disorders, etc.
There are still serious, unsolved problems related to gene therapy. Difficulties include effective integration of the therapeutic genes into the genome of target cells, reducing the risk of an undesired immune response, potential toxicity, immunogenicity, inflammatory responses, and oncogenesis related to the viral vectors used in implanting genes and the sheer complexity of the genetic basis of angiogenesis. The most commonly occurring disorders in humans, such as heart disease, high blood pressure, diabetes and Alzheimer's disease, are most likely caused by the combined effects of variations in many genes, and, thus, injecting a single gene may not be significantly beneficial in such diseases.
In contrast, pro-angiogenic protein therapy uses well-defined, precisely structured proteins, with previously defined optimal doses of the individual protein for disease states, and with well-known biological effects. On the other hand, an obstacle of protein therapy is the mode of delivery. Oral, intravenous, intra-arterial, or intramuscular routes of protein administration are not always as effective, as the therapeutic protein may be metabolized or cleared before it can enter the target tissue. Cell-based pro-angiogenic therapies are still early stages of research, with many open questions regarding best cell types and dosages to use.
Cancer cells are cells that have lost their ability to divide in a controlled fashion. A malignant tumor consists of a population of rapidly dividing and growing cancer cells that progressively accrues mutations. However, tumors need a dedicated blood supply to provide the oxygen and other essential nutrients they require in order to grow beyond a certain size (generally 1–2 mm3).
Tumors induce blood vessel growth (angiogenesis) by secreting various growth factors (e.g. VEGF). Growth factors such as bFGF and VEGF can induce capillary growth into the tumor, which some researchers suspect supply required nutrients, allowing for tumor expansion. Unlike normal blood vessels, tumor blood vessels are dilated with an irregular shape. In 2007, it was discovered that cancerous cells stop producing the anti-VEGF enzyme PKG. In normal cells (but not in cancerous ones), PKG apparently limits beta-catenin, which solicits angiogenesis. Other clinicians believe angiogenesis really serves as a waste pathway, taking away the biological end products secreted by rapidly dividing cancer cells. In either case, angiogenesis is a necessary and required step for transition from a small harmless cluster of cells, often said to be about the size of the metal ball at the end of a ball-point pen, to a large tumor. Angiogenesis is also required for the spread of a tumor, or metastasis. Single cancer cells can break away from an established solid tumor, enter the blood vessel, and be carried to a distant site, where they can implant and begin the growth of a secondary tumor. Evidence now suggests the blood vessel in a given solid tumor may, in fact, be mosaic vessels, composed of endothelial cells and tumor cells. This mosaicity allows for substantial shedding of tumor cells into the vasculature, possibly contributing to the appearance of circulating tumor cells in the peripheral blood of patients with malignancies. The subsequent growth of such metastases will also require a supply of nutrients and oxygen and a waste disposal pathway.
Two independent studies published in the journal Nature in 2010 November confirmed the ability of tumors to make their own blood vessels. When one group found that tumor stem cells could make their own blood vessels and avastin could not inhibit their early differentiation, the other group showed that selective targeting of endothelial cells generated by tumor-derived stem cells in mouse xenografts resulted in tumour reduction. These studies done in glioblastoma model may have implications in other tumors.
Angiogenesis research is a cutting-edge field in cancer research, and recent evidence also suggests traditional therapies, such as radiation therapy, may actually work in part by targeting the genomically stable endothelial cell compartment, rather than the genomically unstable tumor cell compartment. New blood vessel formation is a relatively fragile process, subject to disruptive interference at several levels. In short, the therapy is the selection agent which is being used to kill a cell compartment. Tumor cells evolve resistance rapidly due to rapid generation time (days) and genomic instability (variation), whereas endothelial cells are a good target because of a long generation time (months) and genomic stability (low variation).
Angiogenesis-based tumor therapy relies on natural and synthetic angiogenesis inhibitors like angiostatin, endostatin and tumstatin. These are proteins that mainly originate as specific fragments of pre-existing structural proteins like collagen or plasminogen.
Recently, the first FDA-approved therapy targeted at angiogenesis in cancer came on the market in the US. This is a monoclonal antibody directed against an isoform of VEGF. The commercial name of this antibody is Avastin, and the therapy has been approved for use in colorectal cancer in combination with established chemotherapy.
Angiogenesis represents an excellent therapeutic target for the treatment of cardiovascular disease. It is a potent, physiological process that underlies the natural manner in which our bodies respond to a diminution of blood supply to vital organs, namely the production of new collateral vessels to overcome the ischemic insult. A large number of preclinical studies have been performed with protein-, gene- and cell-based therapies in animal models of cardiac ischemia, as well as models of peripheral artery disease. Reproducible and credible successes in these early animal studies led to high enthusiasm that this new therapeutic approach could be rapidly translated to a clinical benefit for millions of patients in the Western world suffering from these disorders. A decade of clinical testing both gene- and protein-based therapies designed to stimulate angiogenesis in underperfused tissues and organs, however, has led from one disappointment to another. Although all of these preclinical readouts, which offered great promise for the transition of angiogenesis therapy from animals to humans, were in one fashion or another, incorporated into early stage clinical trials, the FDA has, to date (2007), insisted that the primary endpoint for approval of an angiogenic agent must be an improvement in exercise performance of treated patients.
If one reviews in detail the various published angiogenesis clinical trials, it can be realized that most of these trials had success in achieving various secondary or supportive endpoints, but failed when attempting to demonstrate a statistically significant improvement in exercise performance, typically done by a treadmill exercise test. Perhaps the greatest reason for these trials' failure to achieve success is the high occurrence of the "placebo effect" in studies employing treadmill exercise test readout. Thus, even though a majority of the treated patients in these trials experience relief of such clinical symptoms as chest pain (angina), and generally performed better on most efficacy readouts, there were enough "responders" in the blinded placebo groups to render the trial inconclusive. In addition to the placebo effect, more recent animal studies have also highlighted various factors that may inhibit an angiogenesis response, including certain drugs, smoking, and hypercholesterolemia.
Although shown to be relatively safe therapies, no angiogenic therapeutic has yet made it through the gauntlet of clinical testing required for drug approval. By capitalizing on the large database of what did and did not work in previous clinical trials, results from more recent studies with redesigned clinical protocols give renewed hope that angiogenesis therapy will be a treatment choice for sufferers of cardiovascular disease resulting from occluded and/or stenotic vessels.
Early clinical studies with protein-based therapeutics largely focused on the intravenous or intracoronary administration of a particular growth factor to stimulate angiogenesis in the affected tissue or organ. Most of these trials did not achieve statistically significant improvements in their clinical endpoints. This ultimately led to an abandonment of this approach and a widespread belief in the field that protein therapy, especially with a single agent, was not a viable option to treat ischemic cardiovascular disease. However, the failure of gene- or cell-based therapy to deliver a suitable treatment choice for diseases resulting from poor blood flow has led to a resurgence of interest in returning to protein-based therapy to stimulate angiogenesis.
These failures suggested that either these are the wrong molecular targets to induce neovascularization, that they can only be effectively used if formulated and administered correctly, or that their presentation in the context of the overall cellular microenvironment may play a vital role in their utility. It may be necessary to present these proteins in a way that mimics natural signaling events, including the concentration, spatial and temporal profiles, and their simultaneous or sequential presentation with other appropriate factors.
Lessons learned from earlier protein-based studies, which indicated that intravenous or intracoronary delivery of the protein was not efficacious, have led to completed and ongoing clinical trials in which the angiogenic protein is injected directly into the beating ischemic heart.
Such localized administration of the potent angiogenic growth factor, human FGF-1, has recently given promising results in clinical trials in no-option heart patients. Angiogenesis was documented by angiographically visible "blushing", and functional exercise tests were also performed on a subset of patients. The attractiveness of protein therapy is that large amounts of the therapeutic agent can be injected into the ischemic area of interest, to pharmacologically start the process of blood vessel growth and collateral arteries formation. In addition, from pharmacokinetic data collected from the recent FGF-1 studies in the human heart, it appears that FGF-1, once it exits the heart, is cleared in less than three hours from the circulation. This would presumably prevent FGF-1 from stimulating unwanted angiogenesis in other tissues of the bodies where it could potentially cause harm, such as the retina and in the kidneys. No serious adverse events have yet to be noted in any of the completed or ongoing clinical trials in which the FGF-1 protein is used as the therapeutic agent to stimulate angiogenesis.
Left: Angiographic "blushing" following FGF-1 injection into the human heart. Right, measurements of pixel density in angiograms ("gray-value-analysis") indicating a threefold increase in vessel density in the treated human myocardium (3 months and 3 years).
Improvement in myocardial perfusion (blood supply) after FGF-1 treatment as demonstrated by single photon emission computed tomography (SPECT) imaging.
Another approach for stimulation angiogenesis in the heart is using FGF gene (instead of the protein) delivered by adenoviral vectors (e.g. Ad5FGF-4, Generx) during intracoronary infusion. Several clinical trials with angiogenic gene therapy have been completed with promising efficacy and safety data (e.g. AGENT trials). These trials tested intracoronary administration of Ad5FGF-4 in over 450 patients and demonstrated the safety of the product and the procedure. It is notable that when exercise tolerance was used as the primary end-point, the product did not achieve statistically significant effect primarily due to high placebo effect in the control groups. In contrast, when the more objective end-point of SPECT (measuring the extent of reversible myocardial ischemia) was used in the AGENT-2 clinical study, intracoronary administration of Ad5FGF4 resulted in a statistically significant therapeutic effect. Currently ongoing pivotal (Phase 3) clinical studies use myocardial perfusion (as measured by SPECT) as the primary end point.
Angiogenesis is generally associated with aerobic exercise and endurance exercise. While arteriogenesis produces network changes that allow for a large increase in the amount of total flow in a network, angiogenesis causes changes that allow for greater nutrient delivery over a long period of time. Capillaries are designed to provide maximum nutrient delivery efficiency, so an increase in the number of capillaries allows the network to deliver more nutrients in the same amount of time. A greater number of capillaries also allows for greater oxygen exchange in the network. This is vitally important to endurance training, because it allows a person to continue training for an extended period of time. However, no experimental evidence suggests that increased capillarity is required in endurance exercise to increase the maximum oxygen delivery.
Quantifying vasculature parameters such as microvascular density has various complications due to preferential staining or limited representation of tissues by histological sections. Recent research has shown complete 3D reconstruction of tumor vascular structure and quantification of vessel structures in whole tumors in animal models. This has been applied to assessing effects of chemotherapeutic drugs.
1 2 Angiogenesis insights from a systematic overview. New York: Nova Science. 2013. ISBN 978-1-62618-114-4.
↑ Birbrair, Alexander; Zhang, Tan; Wang, Zhong-Min; Messi, Maria Laura; Mintz, Akiva; Delbono, Osvaldo (2015-01-01). "Pericytes at the intersection between tissue regeneration and pathology". Clinical Science. 128 (2): 81–93. doi:10.1042/CS20140278. ISSN 0143-5221. PMC 4200531 . PMID 25236972.
↑ Birbrair, Alexander; Zhang, Tan; Wang, Zhong-Min; Messi, Maria Laura; Olson, John D.; Mintz, Akiva; Delbono, Osvaldo (2014-07-01). "Type-2 pericytes participate in normal and tumoral angiogenesis". American Journal of Physiology. Cell Physiology. 307 (1): C25–C38. doi:10.1152/ajpcell.00084.2014. ISSN 0363-6143. PMC 4080181 . PMID 24788248.
↑ Risau W, Flamme I (1995). "Vasculogenesis.". Annual Review of Cell and Developmental Biology. 11: 73–91. doi:10.1146/annurev.cb.11.110195.000445. PMID 8689573.
↑ Flamme I, Frölich T, Risau W (November 1997). "Molecular mechanisms of vasculogenesis and embryonic angiogenesis". Journal of cellular physiology. 173 (2): 206–10. doi:10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C. PMID 9365523.
↑ John S. Penn (11 March 2008). Retinal and Choroidal Angiogenesis. Springer. pp. 119–. ISBN 978-1-4020-6779-2. Retrieved 26 June 2010.
↑ Burri PH, Hlushchuk R, Djonov V (2004). "Intussusceptive angiogenesis: its emergence, its characteristics, and its significance". Dev Dyn. 231 (3): 474–88. doi:10.1002/dvdy.20184. PMID 15376313.
1 2 3 4 5 Prior BM, Yang HT, Terjung RL (September 2004). "What makes vessels grow with exercise training?". Journal of Applied Physiology. 97 (3): 1119–28. doi:10.1152/japplphysiol.00035.2004. PMID 15333630.
↑ Perhaps an inhibitor of angiogenesis: Sheppard D (October 2002). "Endothelial integrins and angiogenesis: not so simple anymore". The Journal of Clinical Investigation. 110 (7): 913–4. doi:10.1172/JCI16713. PMC 151161 . PMID 12370267.
1 2 3 Mecollari, V; Nieuwenhuis, B; Verhaagen, J (2014). "A perspective on the role of class III semaphorin signaling in central nervous system trauma". Frontiers in Cellular Neuroscience. 8: 328. doi:10.3389/fncel.2014.00328. PMC 4209881 . PMID 25386118.
↑ Ornitz DM, Itoh N (2001). "Fibroblast growth factors". Genome Biology. 2 (3): reviews3005.1–reviews3005.12. doi:10.1186/gb-2001-2-3-reviews3005. PMC 138918 . PMID 11276432. Archived from the original on February 2, 2006.
↑ Blaber M, DiSalvo J, Thomas KA (February 1996). "X-ray crystal structure of human acidic fibroblast growth factor". Biochemistry. 35 (7): 2086–94. doi:10.1021/bi9521755. PMID 8652550.
1 2 3 Stegmann TJ (December 1998). "FGF-1: a human growth factor in the induction of neoangiogenesis". Expert Opinion on Investigational Drugs. 7 (12): 2011–5. doi:10.1517/13543784.7.12.2011. PMID 15991943.
↑ Khurana R, Simons M (April 2003). "Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease". Trends in Cardiovascular Medicine. 13 (3): 116–22. doi:10.1016/S1050-1738(02)00259-1. PMID 12691676.
1 2 Stegmann TJ, Hoppert T, Schneider A, Gemeinhardt S, Köcher M, Ibing R, Strupp G (September 2000). "Induction of myocardial neoangiogenesis by human growth factors. A new therapeutic approach in coronary heart disease". Herz (in German). 25 (6): 589–99. doi:10.1007/PL00001972. PMID 11076317.
1 2 Wagoner, L.E., Snavely, D.D., Conway, G.A., Hauntz, E.A., Merrill, W.H.: Intramyocardial injection of fibroblast growth factor-1 for treatment of refractory angina pectoris: the initial US experience" Circulation 2004; 110: 395.
↑ Goto F, Goto K, Weindel K, Folkman J (November 1993). "Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels". Laboratory Investigation. 69 (5): 508–17. PMID 8246443.
↑ Ding YH, Luan XD, Li J, Rafols JA, Guthinkonda M, Diaz FG, Ding Y (December 2004). "Exercise-induced overexpression of angiogenic factors and reduction of ischemia/reperfusion injury in stroke". Current Neurovascular Research. 1 (5): 411–20. doi:10.2174/1567202043361875. PMID 16181089. Archived from the original on April 19, 2012.
↑ Gavin TP, Robinson CB, Yeager RC, England JA, Nifong LW, Hickner RC (January 2004). "Angiogenic growth factor response to acute systemic exercise in human skeletal muscle". Journal of Applied Physiology. 96 (1): 19–24. doi:10.1152/japplphysiol.00748.2003. PMID 12949011.
↑ Kraus RM, Stallings HW, Yeager RC, Gavin TP (April 2004). "Circulating plasma VEGF response to exercise in sedentary and endurance-trained men". Journal of Applied Physiology. 96 (4): 1445–50. doi:10.1152/japplphysiol.01031.2003. PMID 14660505.
↑ Lloyd PG, Prior BM, Yang HT, Terjung RL (May 2003). "Angiogenic growth factor expression in rat skeletal muscle in response to exercise training". American Journal of Physiology. Heart and Circulatory Physiology. 284 (5): H1668–78. doi:10.1152/ajpheart.00743.2002 (inactive 2015-01-09). PMID 12543634.
↑ Thurston G (October 2003). "Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis". Cell and Tissue Research. 314 (1): 61–8. doi:10.1007/s00441-003-0749-6. PMID 12915980.
↑ Haas TL, Milkiewicz M, Davis SJ, Zhou AL, Egginton S, Brown MD, Madri JA, Hudlicka O (October 1, 2000). "Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle". American Journal of Physiology. Heart and Circulatory Physiology. 279 (4): H1540–7. PMID 11009439.
↑ Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ (February 2007). "Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting". Proceedings of the National Academy of Sciences of the United States of America. 104 (9): 3219–24. Bibcode:2007PNAS..104.3219L. doi:10.1073/pnas.0611206104. PMC 1805530 . PMID 17296940.
↑ Hellström, Mats; Phng, Li-Kun; Hofmann, Jennifer J.; Wallgard, Elisabet; Coultas, Leigh; Lindblom, Per; Alva, Jackelyn; Nilsson, Ann-Katrin; Karlsson, Linda (2007-02-15). "Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis". Nature. 445 (7129): 776–780. doi:10.1038/nature05571. ISSN 1476-4687. PMID 17259973.
↑ Soker, S.; Takashima, S.; Miao, H. Q.; Neufeld, G.; Klagsbrun, M. (1998). "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor". Cell. 92 (6): 735–745. doi:10.1016/s0092-8674(00)81402-6. ISSN 0092-8674. PMID 9529250.
↑ Herzog, B; Pellet-Many, C; Britton, G; Hartzoulakis, B; Zachary, I. C. (2011). "VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation". Molecular Biology of the Cell. 22 (15): 2766–2776. doi:10.1091/mbc.E09-12-1061. ISSN 1939-4586. PMC 3145551 . PMID 21653826.
↑ Ferrara N, Kerbel RS (Dec 15, 2005). "Angiogenesis as a therapeutic target". Nature. 438 (7070): 967–74. Bibcode:2005Natur.438..967F. doi:10.1038/nature04483. PMID 16355214.
↑ Folkman J, Klagsbrun M (January 1987). "Angiogenic factors". Science. 235 (4787): 442–7. Bibcode:1987Sci...235..442F. doi:10.1126/science.2432664. PMID 2432664.
↑ Folkman J (September 1996). "Fighting cancer by attacking its blood supply". Scientific American. 275 (3): 150–4. doi:10.1038/scientificamerican0996-150. PMID 8701285.
↑ Folkman J (February 24, 1998). "Angiogenic therapy of the human heart". Circulation. 97 (7): 628–9. doi:10.1161/01.CIR.97.7.628. PMID 9495294.
↑ Gonzalez-Perez, Ruben R.; Rueda, Bo R. (2013). Tumor angiogenesis regulators (1 ed.). Boca Raton: Taylor & Francis. p. 347. ISBN 978-1466580978. Retrieved 2 October 2014.
↑ Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (October 2004). "Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases". Clin. Cancer Research. 10 (20): 6897–6904. doi:10.1158/1078-0432.CCR-04-0378. PMID 15501967.
↑ Bagri A, Kouros-Mehr H, Leong KG, Plowman GD (2010). "Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale". Trends Mol Med. 16 (3): 122–32. doi:10.1016/j.molmed.2010.01.004. PMID 20189876.
↑ Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V (November 2010). "Glioblastoma stem-like cells give rise to tumour endothelium". Nature. 468 (7325): 829–33. Bibcode:2010Natur.468..829W. doi:10.1038/nature09624. PMID 21102433.
↑ Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R (November 2010). "Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells". Nature. 468 (7325): 824–8. Bibcode:2010Natur.468..824R. doi:10.1038/nature09557. PMID 21102434.
↑ Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK (September 12, 2000). "Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary". Circulation. 102 (11): E73–86. doi:10.1161/01.CIR.102.11.e73. PMID 10982554.
↑ Cao L, Mooney DJ (November 2007). "Spatiotemporal control over growth factor signaling for therapeutic neovascularization". Advanced Drug Delivery Reviews. 59 (13): 1340–50. doi:10.1016/j.addr.2007.08.012. PMC 2581871 . PMID 17868951.
↑ Stegmann TJ (2005). New vessels for the heart : angiogenesis as new treatment for coronary heart (1st ed.). Henderson, NV: CardioVascular Biotherapies Inc. ISBN 978-0-9765583-0-9.
↑ Chia-Chi Chien, Ivan M. Kempson, Cheng Liang Wang et al, "Complete microscale profiling of tumor microangiogenesis" Biotechnology Advances (2011), doi:10.1016/j.biotechadv.2011.12.001.
"Anti-fungal drug stops blood vessel growth". EurekAlert. 2007-04-27.
Angiogenesis - Thomas H. Adair and Jean-Pierre Montani. A textbook on the topic freely available at NCBI.


Our headquarter is Zibo Sanxi Sponge Technology Co., Ltd. which was established in 1999, with nearly 20 years of professional production research, products get much praises from the industry and customers for advanced technology and stable quality. Especially high rebound sponge series, we have the largest output and most stable quality in Shandong Province, even the north China. Our company insists on the business philosophy of professionalism and integrity. We pay more attention to production technology, product quality and customer satisfaction. Materials are all well-known brands at home and abroad, no fake is added; each batch of products must be tested qualified and leave samples before delivery.


The contours of the Kosovo separatists' plan to suppress the Serbian resistance in the northern part of the province with the help of the US and the EU are getting increasingly visible. The statements emanating from Pristina and the intensifying international debates over the Kosovo theme do not only show that the Albanian separatists are preparing an attack against their opponents but also give an idea of its potential scenario, the distribution of roles in it, and the extent to which Hashim Thaci and other former leaders of the terrorist Kosovo liberation army are relying on the international support in the process.
The debates at the January 22 open session of the UN Security Council on Kosovo were unprecedentedly heated. It was the first time since the summer of 2007 (when Russia managed to derail the Resolution recognizing the Kosovo independence, proposed by the West on the basis of UN Special Envoy Martti Ahtisaari's plan) that the parties to the dispute over Kosovo defined their positions with such utmost clarity. There was an impression that the world's major powers were speaking different languages. UN Secretary General Ban Ki-moon, the US, and West European countries "urged flexibility" in admitting Kosovo to regional and international mechanisms and forums, whereas Russia and Serbia regarded the approach as an attempt to dilute the role of the UN in the province and to legitimize its independent status. The discussions were centered around Pristina's so-called final solution plan for North Kosovo, which Thaci inadvertently unveiled several days prior to the session. He said the plan was being drafted jointly with the international representatives and was aimed at strengthening what he called Kosovo sovereignty and territorial integrity. Thaci said 2010 would be the year of consolidation for Kosovo. The priorities in the framework of the plan include the elimination of the Serbian self-government established in Kosovska Mitrovica and nearby Serbian communities based on the May, 2008 elections held in accord with the laws of Serbia. Another blow will be dealt to Serbian police forces and custom service, which at the moment are maintaining at least partial control over the traffic across the administrative border between Kosovo and the rest of Serbia.
NATO's KFOR deployed in Kosovo will render military assistance to Albanians. There is information that on the whole the corresponding decision was made during Commander of Joint Force Command Naples, Admiral Mark Fitzgerald's January visit to Kosovo, after which he described the Serbian self-government as… a threat to the security of Kosovo. "All violations of UN Security Council Resolution 1244 pose a threat to security. Since the resolution does not approve of parallel institutions, they are cause for concern", said Fitzgerald.
Pristina's priority is the international support for the operation, which the US and the EU are supposed to ensure. The US will be blocking the attempts by Russia and China to have a response resolution passed by the UN Security Council. At the same time Brussels will be exerting ever greater pressure on Serbia to make it deny support to the Serbs of Kosovo and seal off the border with the province so as not let Serbian volunteers reach Albania.
Chances are that the operation will be launched already next April after the International Court of Justice issues an indefinite verdict on the Kosovo independence and the establishment of the Mitrovica municipality headed by Albanians and the few Serbs ready to cooperate with them.
Serbia's pro-Western President B. Tadic spoke with great caution of the anti-Serbian plan harbored by Pristina, NATO, and the EU, essentially saying little more than that the "final solution" promised nothing good to the Kosovo population. Russia's Deputy Permanent Representative to UN I. Shcherbak was much more outspoken. He said that from Russia's standpoint it is necessary to arrest decisively any attempts to float concepts harmful to Kosovo regardless of their source, as they do not only breach UN Security Council Resolution 1244 but also destabilize the province and provoke tensions.
There is information that the plan was co-authored by EU Special Representative and UN Civil Administration head Pieter Feith. The Administration was established in the spring of 2008, shortly after the declaration of the Kosovo independence and its recognition by the US and major EU counties. The Administration that no UN documents regulate comprises representatives of 14 EU and NATO countries and Switzerland, which are implementing the Ahtisaari plan, a EU brainchild the UN Security Council never approved. It is noteworthy that Kosovo separatist government foreign minister Skender Hyseni who represented Kosovo at the UN Security Council session made no comments concerning the plan for the northern part of Kosovo. Speaking to the media after the session, he claimed without elaborating that the EU mission and the Civic Administration were not promoting any final solutions for North Kosovo.
A survey of recent developments leads to the conclusion that the blueprint for suppressing the Serbian resistance in Kosovo is being drafted at a level much higher than that of the province. Given its basic parameters (a snap offensive supported by the NATO and EU pseudo-peacekeepers with international political backing plus the installation of a puppet administration), the plan for a final solution for North Kosovo is similar to the one Georgian President M. Saakashvili had in mind launching an attack against South Ossetia in August, 2008. Even the stated objectives – the restoration of the constitutional jurisdiction in Saakashvili's wording – is the same in both cases.
Even earlier, in August, 1995, a similar scenario was imposed on the Serbs of Krajina when Croatia sent regular army forces to attack them while the US and the EU backed the operation diplomatically. Actually, at that time the diplomatic support played no practical role as neither Yugoslavia nor the Russian leadership demonstrated any will to help Serbian Krajina in its tragedy. Yugoslavian leader S. Milosevic took more interest in getting rid of his competitors R. Karadzic and R. Mladic with the hands of the international community, and Moscow paid little if any attention to the whole Balkan theme.
It is hard to predict the outcome of the current developments as the Bosnian front, no less important to Serbs, Russia, and the Orthodoxy, is likely to gain a place on the map of the new Balkan war alongside the Kosovo one. Outgoing Croatian President Stipe Mesic said the Republic's army should launch an offensive against the Bosnian Serb Republic in case it holds a Kosovo-style self-determination referendum.


text:
Kids in rude health
This week's Champion Columnist is Ken Jackson 48, a full-time writer from Northallerton, North Yorkshire.
Over the past 40 years the world has changed dramatically. Many of these changes have been for the better but, unfortunately, in this transition we have lost some of the social niceties which help society to function better as a cohesive unit.
Two of the main social graces which have suffered through social "progress" are manners and respect.
As the old saying goes: "Manners maketh man" and this is as true today as it was way back when.
But, contrary to what the older generations say, this serious moral decline can't all be blamed on our teenagers. After all, they get most of their early, pre-school standards from their parents.
There are any number of reasons for the sad decline in the practice of manners and respect. One of the main reasons, in my opinion, is the mad rush of modern living where everything has to be done yesterday.
The frazzled, frenetic pace of life in 2004 is very different from the altogether steadier world of 1964, where you could finish a job on Friday and start a new one on Monday. Such a fact sounds incredible to us today.
Because everyone is now in such a rush it leaves us little time for the consideration of the needs of other people.
Some of the blame must also lie at the door of the mass media - films, newspapers and television - who often shirk responsibility for the things that they do.
But probably the main problems stem from the "anything goes" culture which came in during the mid-to-late 1960s, when we were invited to "turn on, tune in and drop out".
Unfortunately the overlying mantra was to do things rather than not do them . . . to have sex and drink as soon as possible, to break the law as soon as you could or take drugs as early as possible, and so on.
The emergence of the anti-hero has also been an undesirable factor. Anti-heroes pour scorn on respect, civility and virtue. There is hardly anything noble about their behaviour.
How can impressionable young children and teenagers gain standards from role models like these? In the late 1950s and early 1960s it was, thankfully, a different story. Youngsters could escape into a fantasy, a noble world with Richard the Lionheart, The Adventures of William Tell and Robin Hood, Sir Francis Drake and other well-known children's TV programmes. What role models they were!
They also helped to give you a sense of history, conveyed the importance of standing up for a good cause and, needless to say, of manners and respect.
Now let me turn to the subject of parents and schools. We have the spectre of latch-key kids, left to their own devices for too long, often because of economic necessity.
Lack of time and other pressures often mean that such children are not taught right from wrong and, in a fiercely competitive world, the attitude can be: "What do manners and respect matter anyway?"
At secondary school such an outlook is often compounded. My 14-year-old daughter used to laugh heartily at me when I suggested she should have respect for her teachers.
"Why, when they haven't done anything to deserve it?" was her dismissive attitude.
What was most hurtful was when she asked why she should have respect for me.
In the late 1960s it was compulsory at my secondary school for boys to doff their caps at the teachers when they arrived at school and we all sprang to our feet when our head teacher passed by.
Many kids frowned on having to do this, but I think some of the standards rubbed off.
The demise of school assemblies and religious education teaching has also been a retrograde step in my view.
The high moral standards laid down in the Bible - in The Sermon on the Mount, Ten Commandments, Proverbs and Beatitudes - gave school life a more spiritual basis.
Just remember, we have only one precious life and one precious world and we are sent here to help each other through what is often a trying and difficult passage.
A little more thought and consideration will make it a better world for all of us. So I would make a plea to people to put the needs of others first sometimes.


Join Colin Best and Chuck Charlton on a flight above Milton, Ontario in the spring of 2012.
Google Maps? Naw, we're bringing you the view of town from a small Cessna plane.
Discover the Escarpment, the new sandy beach, ski hills, new development, Main Street zoning and the new Boyne survey. What does the future hold for the Town of Milton? Join us in the air to find out!


For corporate America, recruiting talent is now Job #1.
"Attracting and retaining talent" is now the top issue facing CEOs, according to a 2019 Conference Board survey of 800 CEOs. Companies are having to fight much harder to recruit and keep employees in today's tighter labor market.
While there are many ways to attract and retain top talent, branded environments have emerged as a way to create an appealing work space that charms potential new hires and makes existing employees happier, more productive, and less likely to leave.
Imagine what a potential job recruit would think, entering and touring your facility while on a job interview. Would your facility inspire these same thoughts?
Company culture is at the heart of successful employee recruitment and retention. Why is that? Because your company retains more employees when they join already knowing that they fit well with your company purpose and culture.
Well-designed branded environments strongly communicate your purpose and culture, helping to attract good-fit candidates and discourage bad-fit candidates. Good-fit candidates will be more invested in your mission, and more likely to remain long-time employees. Lowering turnover reduces the cost of recruiting, hiring, and training replacement employees.
According to Pricewaterhouse Coopers (PwC), "Design of the workplace and work" is one of three areas companies are focusing on to create a better employee experience, in order to retain more employees.
Your employees can be your most valuable brand ambassadors. When your employees deeply understand your brand, they can better articulate it to their friends, peers, colleagues and neighbors – among which are potential new employees. You gain a stronger recruiting network, with your employee brand ambassadors at the hub.
You can accelerate your employees' brand awareness and buy-in through branded environments within your facility. Employees working within branded environments daily absorb your brand messages and gain a stronger sense of what your brand stands for.
While much of employer branding focuses on managing and improving your online and social media reputation, your facilities also help bolster your employer brand as well. The #3 most important attribute of a employer brand is a "creative and dynamic work environment," according to Universum, which originated the employer branding concept.
Your facility has a few high-profile spaces that are seen by many groups, and many more that are seen only by employees.
Because spaces such as lobbies and elevator banks are seen by everyone who enters your facility, you harness more branding value when converting these areas into branded environments. You get sales and marketing value from client and prospect visits, plus recruiting and retention value from job candidate and employee visits.
If your company is aggressively competing for new and current employees with other employers in your area, you will benefit by expanding the reach of branded environments in your facility, to reinforce your brand value, and provide a more appealing work space.
Branded environments can help your company achieve many strategic goals, from increasing innovation to increasing sales. But all these goals are in jeopardy without a reliable team of company employees to execute your strategies. In today's tight labor market, branded environments can help excite and inspire current and potential employees that your company brand and mission is aligned with their own interests.
We would love to help you design and build your own company's first branded environment, or to enhance and expand your use of branded environments within your facilities. Contact us today to get started.


Provide comfort for the family of Rita O'Gara with a meaningful gesture of sympathy.
Rita O'Gara, age 96, passed away peacefully on Tuesday, March 19, 2019 at the Iroquois Nursing Home in Jamesville, NY. Rita, a longtime resident of Saranac Lake, NY moved to Fayetteville, NY in the fall of 2007 to be with her daughter, Linda Tait. Nine years later she became a resident at the Iroquois where she touched many lives. Her family is grateful for the comfort and care demonstrated by the staff members at the Iroquois during the past two and half years as well as for the love and support provided to her by dear friends, Pat Albin and Audrey Maloney. Rita is also survived by her grandson Gregory (Kathleen) Tait, two great-grandsons, Alexander James and Owen Sawyer, and many loving nieces and nephews.
Rita was born on October 7, 1922, in Champlain, NY and was the 6th child of the late Gustave and Laura Filion. Upon completion of her education at St. Mary's Academy in Champlain NY, Rita moved to Saranac Lake where she met and married the love of her life, John Richard O'Gara, and later gave birth to her daughter, Linda. She is predeceased by her husband John, and 8 siblings; Irene, John, Andrew, Eva, Joseph, Cecile, Jeanne and Anna.
When Rita arrived in Saranac Lake, she waitressed at the Will Rodgers Memorial Hospital until she was hired by NY Telephone, now known as Verizon. She was initially trained as a telephone operator and later, she was also a supervisor in that department. Rita retired after 34 years with the company and her official retirement date is the same day as the birth of her grandson Gregory, who she delighted in spending time with in Syracuse, NY.
During her time with Verizon, Rita's ability to speak both English and French fluently was a great asset to the company. This was particularly evident when she was chosen to work during the 1980 Olympics in the Verizon Venue, assisting French speaking visitors from around the world. Rita always enjoyed her job but spoke of that magical time in this international event as one of the most exciting and rewarding times of her life.
While employed by Verizon, Rita was an active member of the Telephone Pioneers of America. This group met regularly and volunteered their time and money to help make a difference in their community. As part of her volunteer efforts, Rita knitted over 1200 baby hats for newborns at the Saranac Lake General Hospital. She was also a devout Catholic who attended daily mass for over 35 years and participated in prayer ministry for those who were facing difficult challenges. She was a member of the Catholic Daughters of America for over 50+ years and an enthusiastic volunteer for St. Bernard's Church, helping when and where she could. Rita loved Saranac Lake and was very proud of her community and its rich history.
A funeral mass and burial will take place in Saranac Lake this spring with the date to be announced. Memorial contributions for Rita can be made to Immaculate Conception Church, 400 Salt Springs Road, Fayetteville NY 13066 or to St. Bernard's Church, 27 St. Bernard Street, Saranac Lake, NY 12983. Family and friends may also wish to share their memories of Rita and sign the online guest books.
Dear Linda, we were so sad to read the obituary and and see the news about your mom. It certainly brought back fond memories of our trip to the Lake Placid soccer camp, and seeing her at the kids soccer games. We are so sorry for your loss. She will be missed.


My Cancer Care Record is a resource that supports people affected by cancer to store and record their medical and health-related information in one place.
It also provides tips on questions and information to ask health professionals and a single place to record and recall specific details or instructions that can be hard to remember.
My Cancer Care Record is a folder with eight key section dividers, to help you organise your medical information.
Cancer care can be complex and challenging; can involve multiple treatments provided by multiple people, across different services and over long periods of time. This resource can assist you to keep abreast of your information, to be able to communicate this across the variety of health care professionals involved in your care.
The development of this resource has been led by a very dedicated consumer group – people with their own personal experience of cancer. Clinical expertise was provided by health care professionals across a variety of cancer health care services, including Cancer Council Victoria.
Currently 2000 copies of the resource are being provided to cancer patients in the Grampians and NEMICS regions. Users of My Cancer Care Record will be surveyed to evaluate how the resource is being used and how helpful it is.


When searching for dumpster rentals in Cornish, ME, it's worth your while to really take some time and do your research. Choose Casella to provide your dumpster rentals in Cornish, ME, and you'll receive affordable, professional service that's sure to help assist your project's timely completion. Whether you need a dumpster rental for a home renovation, clean-up project or for a worksite, when you need a reasonably priced and reliable dumpster rentals in Cornish, ME, make Casella your first choice.
What Separates Casella from the Other Dumpster Rentals in Cornish, ME?
We take the guesswork out of pricing, by ensuring that your price quote on dumpster rentals in Cornish, ME is inclusive. It's a less complicated way to get accurate dumpster rentals in Cornish, ME.
Dumpster Rentals in Cornish, ME are designed to work with your individual needs, because we know that a small home or office clutter removal project doesn't have the same requirements as a construction site. It's the personal touch that makes Casella stand apart from other companies offering dumpster rentals in Cornish, ME.
You will feel satisfied once you receive the dumpster rentals in Cornish, ME from Casella. Our primary concern is your customer satisfaction. We hold a strong commitment to protecting the environment and converting waste into reusable energy. We also do our part to ensure a safe, sustainable community, protecting resources, the public and the community in which we live and work.


In power, in fame, in lucrative pay.
The happiness these bring is fleeting indeed.
We want the kind that endures—guaranteed.
For whatever else happens, that we can choose.
But always it matters, and sometimes a lot.
To be even-minded and cheerful of heart.
Be ever awake and ready to go.
Of all that life brings, for it's from the Divine.
Seek only the Spirit, and stay in your spine.
Say "Yes!" to life, if joy is your goal.
Take charge of your attitude. Live from your soul!
Then happiness won't have to wait one more day.
For it isn't complex, and it's not far away.
You're living your life in the here and the now.


I have to agree. It's probably 1 of the coolest pieces of YPS I own and Yep, I have alot lol.
How about a 10oz version in 4D? Probably be a while but it's on the to-do list.
Gravy, a 4d 10 ounce holding in the hand would be killer.
There already is a 2 ounce Heart. Is this the 1st piece we are duplicating same size, just different year?
Schwartzy wrote: There already is a 2 ounce Heart. Is this the 1st piece we are duplicating same size, just different year?
There are several annual bars.
It's the same weight as the 2016 Valentine heart (which doesn't have a year stamp), but the dimensions look different. This looks like it will be chunkier.
I'm not a big gun guy, but, the Derringer is much better in hand than the pics. Really a cool piece! Nice job David!
10 oz 4D version would be cool, but, I'm still waiting on those 10 oz turtle shells and Egyptian pyramids!
1 oz Ankh and Derringer are definitely contenders for best pieces of recent.
This is a chunkier version. It uses the same mold as last years 3oz. Only so many sizes to make as I like to keep these annual bars under 100g. Maybe next year I can get max gravy to make a cool heart design. I just ran out of time with everything else going on and being out of work sick most of the last month.
SS individual bars are up, but the sets are still saying "coming soon".
I wonder if he is having problems with the site.
Last edited by Rik Bitter on Sun Jan 27, 2019, edited 1 time in total.
The moment we give up it's going to come online.
It's like a loyalty test.
EDIT: It's up!!! I got in within the first 20 so maybe I'll get my numbers. Woot!
Rik Bitter wrote: The moment we give up it's going to come online.
How did you know you got in in the first 20?
After I ordered I went back to the page and it said there were still 34 in stock.
50 - 34 < 20.


text:
With LinkedIn, Microsoft looks to get back to the heart of the enterprise
Microsoft covets LinkedIn algorithms
I don't want to be LinkedIn with Microsoft
5 ways to attract and retain female technologists
Microsoft scoops up LinkedIn for $26.2B in cash
LinkedIn CEO Jeff Weiner will remain, reporting to Microsoft CEO Satya Nadella
By Blair Hanley Frank
U.S. Correspondent, IDG News Service |
Microsoft has made a big bet on LinkedIn, announcing Monday that it will spend nearly $26.2 billion in cash to purchase the enterprise-focused social networking and recruiting company.
The acquisition, the largest in Microsoft's history and one of the biggest tech acquisitions ever, will combine the world's largest enterprise-focused social network with one of the biggest enterprise software companies.
The deal is more than just a social play. In addition to LinkedIn's core professional networking product, Microsoft also gains access to products including presentation-sharing software SlideShare and professional training service Lynda.com.
One key purpose of the deal is to expand Microsoft's portfolio of software that reaches users at work, in a variety of different scenarios.
In a video accompanying the acquisition announcement, Microsoft CEO Satya Nadella presented a vision for productivity tools that are connected to a professional network and can help users improve at their jobs and find new ones as well.
Microsoft sees a future where everyone's LinkedIn profile connects with all of their productivity apps, and automatically syncs information between Office apps. Furthermore, Microsoft plans to drive further personalization of its Cortana virtual assistant using LinkedIn information, so users can get details about upcoming meetings based on the profiles of the people they're meeting with.
LinkedIn has 433 million registered users worldwide, with 105 million of those users visiting the social network every month. Those are attractive numbers for Microsoft, especially since those people are potential customers for many of the company's products and services.
Jeff Weiner, LinkedIn's CEO, will retain control of the company's operations and will report directly to Microsoft CEO Satya Nadella. Microsoft said that LinkedIn will retain its brand, culture and independence after the acquisition, which is expected to close by the end of this year.
It's unclear how far that independence will stretch. Microsoft didn't say whether it plans to leave LinkedIn's HR department independent of the company's central processes in Redmond, Wash., for example.
The news comes at a tumultuous time for LinkedIn, which has been performing poorly on Wall Street since the start of 2016. The company's fourth-quarter earnings from 2015 disappointed investors, and its stock hasn't been able to recover from that precipitous drop.
It also may be a tough pill for Microsoft shareholders to swallow, considering that the company just finished writing down almost all of the value from its acquisition of Nokia in 2013. Since then, Microsoft has massively curtailed its ambitions of being a phone manufacturer and taken $8 billion in write-downs.
Microsoft will pay for the massive bill largely by taking on new debt. It has been approved by the boards of both companies, as well as by Reid Hoffman, the LinkedIn co-founder, who remains the company's majority shareholder.
Blair Hanley Frank is primarily focused on the public cloud, productivity and operating systems businesses for the IDG News Service.


text:
Home » Economy » India, South African Ministers 'discussed plans for TRIPS waiver push'
India, South African Ministers 'discussed plans for TRIPS waiver push'
We held talks hours before WTO meet was called off, says Commerce Minister Piyush Goyal
Hours before the World Trade Organisation (WTO) called off its upcoming ministerial meeting, Commerce and Industry Minister Piyush Goyal spoke to his South African counterpart Ebrahim Patel over contingency plans to pilot their joint proposal for a waiver in the TRIPS agreement to counter the pandemic.
Mr. Goyal and Mr. Patel, Minister for Trade, Industry and Competition, spoke over the phone after it had become apparent late on Friday that the latter would not be able to travel to Geneva for the WTO ministerial council meeting due to travel restrictions triggered by the latest variant of the virus.
"As you know, the meeting has also been postponed and rightly so, I am glad. Even late last [Friday] night, at about 1:30 I was talking to my South African counterpart who is now not able to travel to Geneva because of the travel restrictions," Mr. Goyal said, in his first statement on the deferral of the critical talks that were to begin on November 30.
"We were wondering how we are going to negotiate the TRIPS waiver to provide the WTO response to the pandemic. Both of us agreed that we will pitch for a cancellation or a postponement of this MC-12. Not that I made any calls, but he was going to be talking to the WTO Director General [Ngozi Okonjo-Iweala] after our chat. I am delighted that within an hour and a half of that, we heard that the MC-12 has been cancelled," Mr. Goyal said at an interaction with the CII.
While the Indian economy's key indicators are showing healthy growth, the Minister said there are concerns around "what's happening in Europe, and also particularly in South Africa", referring to the fresh lockdowns in parts of Europe and the emergence of the Omicron variant.
India, South Africa and Indonesia are jointly seeking a waiver to certain provisions of the WTO agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) to enable more affordable access to vaccines and medicines for coping with the pandemic.
Professor Carlos Correa, executive director at the Geneva-based South Centre, said developing countries should use the time available due to the postponement of the meet to consolidate their positions on various issues including fisheries subsidies, agriculture, TRIPS waiver and the Special and Differential Treatment norms. He was speaking at a programme held by the Research and Information System for Developing Countries (RIS) to launch its World Trade and Development Report.
RIS chairman Mohan Kumar also emphasised on developing countries "to get their act together by looking at the opportunities and challenges that have emerged due to the postponement. Ensuring 'success of the MC12 at any cost' should not mean that 'success' is cornered by the developed world and developing countries are left to bear the 'costs'," he said.
Gap, Banana Republic to close more than 225 stores this year
One in two people globally lost income due to the pandemic – Gallup
German Economy Shrinks Most Since 2009 In Q1, Enters Recession
Home price gains moderate for first time in the last year
UK Households' Financial Health Remains Weak Amid Covid-19 Pandemic
Previous Post:Northern Ireland is huge in TV, but post-Brexit reality is far less glitzy
Next Post:Goodbye to job: how the pandemic changed Americans' attitude to work


Large orange/yellow round beefsteak heritage tomato on indeterminate plants.
This Orange/Yellow relatively large (5-8 ounce) fairly round tomato has a sweet flavour and a smooth texture without getting to be mealy. We grew it in 2014 when it didn't crop as well as Summer Cider although (in some respects) it was better (it doesn't have the fluted skin of Summer Cider and is therefore easier to skin if you want to).
It also has more juice than Summer Cider, but this means less flesh. However, they seem to keep better that Summer Cider once picked.
Its a vigorous plant with lots of leaves (which makes it a nuisance in the UK where there's not much sunlight and the leaves should be taken off to help the fruit ripen.
It is said to be a Japanese variety dating back to 1964.
We like it but have to find space against other orange varieties.
This entry was posted in Greenhouse, Tomato Cultivars, Vegetables and tagged Beefsteak, Mandarin Cross, Orange Tomato, Tomato, Tomato Cultivar, Tomatoes. Bookmark the permalink.


Donegal, a much weakend force since last year due emigration and departures, were beaten by 11 points by All-Ireland champions Cork on their NFL visit to Ballyshannon. The score line is deceptive as the game was far from one way traffic. Donegal passed up two clear goal opportunities in the first half and put a third off the cross bar in the second. Geraldine McLaughlin ran up 1-4 for the Tir Chonaill girls, but Cork's experience and goals proved the difference. The Cork manager, Eamonn Ryan, was very gracious after the game complimenting the club the venue and hospitality.


COLUMBUS, Ohio (AP) - Donald Trump's campaign is denouncing and severing ties with Ohio Republican Party Chairman Matt Borges.
It's the latest crack in GOP unity in a critical battleground state where Republican Gov. John Kasich isn't supporting the party's presidential nominee. Borges has been openly critical of Trump on several occasions and has told some Ohio news outlets he wasn't sure if he'd vote for Trump.
Trump Ohio chairman Bob Paduchik is accusing Borges of undermining Trump as part of a bid to be the next Republican National Committee chair. Borges has been mentioned as a possible successor to the current chair, Reince Priebus.
Paduchik says in a letter to state committee members that Trump is "very disappointed in Matt's duplicity."
Borges did not immediately respond to a request for comment.


text:
Q: Multiple indices under a single name in kibana is possible? I want multiple indices to be under one name.. How can i do that in kibana... as shown in this picture..so that the logs ( app,server,db) of the server1 and the logs of server 2 under it. How can we customize to make multiple indices under one name. { http://i.stack.imgur.com/t3eV8.png }

A: I'm not sure if i understood perfectly but you can use an index pattern in kibana like "server*"
Or an other possibility would be to add alias to your indices, they would be accessible with the same index name in kibana

redpajama_set_name: RedPajamaStackExchange


text:
Codefresh launches its hosted GitOps solution
Frederic Lardinois @fredericl / 6 months
Codefresh today announced the launch of its hosted GitOps service based on the Kubernetes-centric Argo open source project. The new hosted service, which will be available for free to community projects, individuals and small teams, aims to give DevOps teams access to a GitOps platform that encodes some of the industry's best practices while still giving those teams the flexibility to tweak it to their needs.
It's worth noting that Argo offers quite a bit more than "just" Argo CD and earlier this year, Codefresh launched support for Argo Workflows, Rollouts and Events as part of its overall platform. But that was for self-hosted installation. Now, with the launch of hosted Argo CD, Codefresh also offers an end-to-end hosted GitOps platform.
"This is basically doing for Argo and GitOps what GitHub did for git," CodeFresh co-founder and Chief Open Source Officer Dan Garfied told me. "We're providing that fully hosted turnkey experience. You just show up, connect your cluster, deploy an application and you're off to the races. You don't have to manage it, you don't have to update it, you don't have to think about it — it's just taken care of for you."
He noted that when the company launched its first Argo CD GitOps solution in 2020, it quickly became its most popular product. And while Codefresh also offers its own continuous integration (CI) service, Garfield stressed that users can also connect the service to the likes of Jenkins and GitHub, too. "We see so many people coming in to GitOps who don't want to rethink the CI part of the equation," he said. "So now you can just connect it and it will automatically show up in your GitOps dashboards and give you all of that extra information that's so helpful for remediation and pulling up these insights."
Image Credits: Codefresh
A hosted GitOps platform removes that barrier for users who want to change the way they are deploying while letting them keep their integration pipelines in place. And that, Garfield stressed, is very much in line with the company's focus on integrating with other third-party services to help its users deliver their software to their customers. With Codefresh as the integration point, those users then also get consolidated dashboards, no matter whether they are using GitLab, Bitbucket or both.
"Codefresh has demonstrated to enterprises of all sizes the value inherent to Argo CD, and this value is built atop a sustained commitment from Codefresh and the community to cultivate Argo and GitOps for the future," said Raziel Tabib, co-founder and CEO, Codefresh. "To empower everyone with this capability is the fullest expression of our commitment to open source innovation."
Current Codefresh customers include the likes of GoodRX, Skillshare and Monday.com. Looking ahead, these users will also likely see Codefresh do more with the overall insights it gets about its users' development and deployment data that flows through its systems and third-party observability tools. While the company doesn't want to get into the observability space itself. Codefresh wants to become the central hub for giving its users insights into what's going on with their deployments, especially as more development teams move to progressive delivery with canary deployments and the inevitable rollbacks when things go wrong.


text:
Ecologically Optimized Finish
Just Like Nature
For millions of years nature has been developing unequalled solutions to many differing requirements. Today, science use the development concepts of nature and transfer them into fascinating technical applications.
This method is focused in the term "Bionic".
With BIONIC-FINISH-RUDOLF® we have developed a unique, patented system for the water repellent or the combined water repellent, oil repellent and soil repellent finish of textiles. Contrary to conventional technologies we make use of the self-orientation of star-shapedly branched polymers (so-called dendrimers), which allows the only complete fibre protection system worldwide, from industrial textile finishing (flock, yarn, piece or garment) to household wear and care.
Learned from nature
In millions of years, nature has developed unique solutions for the most diverse requirements. Today, science makes use of nature's development concepts and applies them to fascinating technical applications.
This method finds its focus in the term Bionic, which means learning from nature. Technical applications, which have been developed from Bionic, are today to be found in the automotive, aircraft and construction industry.
The number 1 of the oceans serves as a model for technical solutions
What is Bionic? How does Bionic work?
The shark furnishes the best explanations. His hydrodynamic shape is highly adapted and makes him the perfect hunter of the oceans. Apart from his hunting strategy, is this the only property that makes him successful? Has nature only for this reason left the basic structure unchanged for more than 100 million years?
Contrary to the assumption that the shark's skin is a smooth surface, it was found that it is coarse. Microscopically small longitudinal grooves, so-called riblets, make the water pass their bodies in a controlled manner, because they reduce friction in the water. This is why there is no other, faster hunter in the water than the shark. The shark-skin effect of competitive swimsuits thus is one of the most well-known findings of Bionic.
Since many hydrodynamic laws are also valid for aerodynamics, aerodynamic transfers to the automobile and aircraft construction following the example of the shark are not a coincidence.
The use of surface structures that are similar to those of the shark's skin save fuel. A transfer to textile applications can be found in swimming. Competitive swimmers can glide faster in water with bionically optimised swimsuits.
BIONIC-FINISH RUDOLF®
The world-wide first complete water-repellent system for the textile industry
The result of intensive R&D work is a patented product system, based on the findings of a Bionic system. By the use of starlike, branched polymers , water and oil-repellent effects with a simultaneously reduced fluorocarbon resin content can be obtained.
RUDOLF GROUP synthetise these hyperbranched polymers, which are capable of building up crystal structures, that produce wash and highly abrasion-resistant, water-repellent effects.
Dendrimers have the ability to self-organise. Complex crystallisation processes, which are triggered off after the application to textiles, are very important here.
An invisible, water-repellent protective shield forms on the textile due to crystallisation, the orientation of dedrimers and the connection to the textile surface.
Depending on the requirements special additives cause an extension of the effects with regard to oil- and soil-repellency, resistance to washing/dry cleaning, but also to mechanical abrasion.
Thus a complete product line of effect- and process-optimised products arises from the dendrimer chemistry, which are marketed under the names ®RUCO-DRY (FC-free) and ®RUCOSTAR (FC-containing).
We are happy to assist you in implementing the process on your articles.


MANILA IN THE '60s MAKES FILIPINOS CRY: I WANT THE "OLD PHILIPPINES"
MANILA, JULY 29, 2013 (PHILSTAR) By Camille Diola (philstar.com) - A screengrab from the video presenting Manila in the 1960's.
PNoy's "Philippine Development Plan 2012-2016"
The Philippine Development Plan (PDP) 2011-2016 is the country's development framework that seeks to address poverty, create massive employment opportunities, and achieve an inclusive growth, a growth that is shared by all. It is not the trickle-down, jobless growth that the country has experienced in the past. BY NEDA.


text:
Tax Reform, Taxation
Bruce Bartlett's Mistake
I wrote on Friday:
Bruce's bottom line may be right, but there's something fishy about these numbers. Start with the fact that the median income for the whole country is at or around the bottom end of this bracket. That means that there are fewer people at, say, $90,000 than at, say, $60,000. So the average in this $50K to $100K bracket is likely to be no higher than $75K and most likely lower. Is it really plausible that the average taxpayer deduction is over $26K?
It gets fishier. Look at the medical deduction. To take that, you must have out-of-pocket medical expenses that exceed 7.5% of your adjusted gross income and you can take only the portion that exceeds that 7.5%. Most people in this income bracket will, therefore, get a big fat zero for the medical deduction. It's highly implausible that the average is over $7,000. With all the zeros, I would expect the average to be under $2,000 and probably well under.
I suspected that the average was simply for people who took the medical deduction. My suspicion was confirmed. Here's a link that explains that fact for data from 2010. HT to Mike Davis of SMU for this link.
The medical deduction number for people with income between $50K and $100K, at $6,690, is similar to Bruce's $7,269. Notice the statement:
Also, note that these averages take into account only those individuals who claimed an itemized deduction for that type of expense.
So with, I would bet, over 80% of taxpayers taking a zero deduction for medical, for reasons explained in the previous post, the average would be under $2,000.
The Wall Street Journal editors also weighed in on this. They don't give a comparable income category. Theirs is $75,000 to $100,000. But they base their numbers on IRS Statistics of Income, which is, recall, what I said Bruce Bartlett should have used.
One would expect, and I'm virtually positive that it's true, that people in this income category have higher average deductions than people in the $50,000 to $100,000 category. The average deduction for people in the $75K to $100K category who itemize is $22,171, well below Bruce's alleged $26,424 for the $50K to $100K income group.
So what happened? Bruce Bartlett cherry-picked and added up numbers that shouldn't be added. Recall that he wrote:
According to data released earlier this year, taxpayers who declared between $50,000 and $100,000 of income in 2009, claimed, on average, $7,269 for medical expenses, $6,247 for taxes, $10,133 for interest and $2,775 for charitable contributions. That sums to $26,424 – well above both figures Romney has put forward.
If his first statement were true, then he should add. But it isn't. Taxpayers who itemized claimed on average much less in medical and, for that matter, less in interest and charitable than those numbers. Again, Bruce forgot to include those with zeros in the various categories.
Categories: Tax Reform Taxation
Oct 21 2012 at 6:22pm
It's also important to note the low number of taxpayers who itemize their tax returns (a little under 30%): http://www.taxpolicycenter.org/numbers/displayatab.cfm?Docid=3549
And the average taxpayer who would reach the proposed cap are within the top 10% of income. There are individuals in much lower tax brackets who would reach the limit, but they are a small percentage of a small percentage (and likely have no taxable income after the $25k deduction and personal exemptions).
COLLECTION: TAX REFORM
The article you're reading is part of Econlib's Tax Reform collection. Explore other Tax Reform articles:
Giving USA Gets the Incentives Half Right
Cowen on Optimal Marginal Tax Rates on CEOs
CBO As Agenda Setter on Tax Policy
Are Matt Yglesias's Words That Wise?


1963 Ford Galaxie Fastback - Fast Forward!
When we saw this Wimbledon White '63 Galaxie at a Utah car show four years ago, it got our attention. It was a striking, slippery, stylish fastback massaged to perfection in Ford's design studios five decades ago. The '631/2 Galaxie fastback symbolized a new mindset at Ford that spring. The Galaxie's fastback roofline was the brainchild of Ford Division General Manager Lee Iacocca, who wanted more sportiness in all Ford car lines. The Falcon also got a fastback roofline and a sporty name--Sprint}. Iacocca infused a totally new image into the Ford Division lineup called Total Performance. Showroom floors quaked; so did the racing world.
Closer inspection of this slippery Galaxie revealed the legendary crossed checkered flags and a portension of things to come--SOHC. This was a 427 Galaxie fastback born of Ford's new, aggressive attitude and the Total Performance era. When Jack hopped in the car and spun its FE big-block, it had a decidedly different sound beneath the teardrop hood. There was the whiz of timing chains and the chatter of 16 rocker arms. Jack goosed the throttle, and we felt a rush of adrenaline. We had discovered not only a lightweight Galaxie, but also one fitted with a N.O.S. 427 SOHC big-block screamer that had just roared up from the '60s.
Jack is passionate about old Ford factory drag racers, but that's getting ahead of ourselves. Jack's love of vintage Fords dates back to when these cars were new, and it has never faded. A friend of his purchased a '63 Galaxie XL convertible in 1986, and Jack fell in love with '63 Fords all over again. He just had to have one. Today, he has five of them--all in various forms with 390s and 427s. Jack found this '63 lightweight in Hemming's Motor News in August 1999. He traded a '97 Camaro SS LT4, plus some cash, to get his hands on this Galaxie lightweight. Jack's find wasn't your typical glass Galaxie. It was fitted with the rare 427 SOHC hemi-head big-block designed and built for NASCAR competition in the mid-'60s.
When NASCAR told Ford it could not compete with an overhead cam engine, Ford wound up with dozens of 427-inch cammers on its hands. Many of them wound up in drag racers. Others were installed in boats. Still others were installed in street drivers. This is one of the crate engines that went undiscovered for many years. When it was discovered, it was knocked down and thoroughly inspected before assembly and fire-up. Jack tells us he removed the original sodium-filled valves and opted for Manley stopcocks instead. When he spun the cammer on the dyno, it made 675 hp at 7,500 rpm. It's a scream still heard high in the stratosphere over Utah.
You couldn't imagine anything less than an adequate drivetrain behind a 700-horse FE big-block. Ford's Top Loader four-speed channels the ponies into a "N" case 9-inch Detroit Locker, sporting 4.11:1 gears for good measure. Jack built his cammer glasser much as you might have expected in the '60s: factory drum brakes at all four corners, American Torq-Thrust D wheels, Mickey Thompson tires, N.O.S. factory Autolite shock absorbers, a 17-inch steering wheel, lightweight bucket seats, and only the necessary instrumentation. The sun tach takes us on a time trip back to the smell of burning rubber and Sunoco 260.
Of course, the centerpiece of this ride is its beating heart from the Total Performance era. The FE-series, 427ci, single overhead cam big-block was born in 1964 for NASCAR competition. It was a corporate act of desperation because Ford was getting clobbered on the superspeedways by Chrysler power. The FE's architecture made it challenging to fit with hemispherical cylinder heads as Chrysler had done with its 426ci RB-block. Because Ford had experience with overhead cam technology in its high-revving Indy small-blocks, it seemed logical to apply this thinking to the FE big-block. What Ford didn't know was NASCAR's Bill France wasn't having any part of overhead cam power on his speedways. Ford would quickly learn there would be no SOHC racing, so they took their corporate ball and went home.
What made the 427 SOHC revolutionary at the time was the technology practiced by Ford engineers. The SOHC's bottom end wasn't much different than we find with the wedge variants. Outside of oil distribution to the unusual heads, the block is virtually the same. Down under is a 7.5-quart oil pan. The crank was a steel forging for obvious reasons. Where the SOHC differed greatly was in its hemispherical crossflow heads with 2.250-inch intake and 1.90-inch exhaust valves. The head gaskets certainly were unique with an asbestos/steel combination designed for extreme pressures and heat. Rocker arms were little more than a cast-iron construction supported by needle-bearing fulcrums. These engines were quite sophisticated for their day--fitted with dual timing chains that looped from the crank sprocket to the single overhead cams above. Chain slack could be adjusted via a single idler. Screw-in freeze plugs were incorporated due to the high cooling system pressures. Ford opted for a transistorized, dual-point ignition system for added measure to keep the fire lit at high rpm.
The most remarkable part of the 427 SOHC story is how quickly Ford went from concept to running test mules--just 90 days. When Ford took its cammer to the dyno labs in Dearborn, it witnessed more than 600 hp at 7,000 rpm with more than 500 lb-ft of torque.
And this brings us back to Jack, who fires his 427 SOHC once a month to keep the oil circulating, and parts nice and limber. For Jack, listening to the SOHC enables him to live a dream most of us will never experience. Because Jack lives out in the country, he's able to spin the twin cams as aggressively as he desires. We will leave the rest to your imagination, and Jack to the business of door slamming.
1963 Ford Galaxie Fastback - "R" Is For Racing!
Vintage Ford Popular Swaps - Swap It!
Join Mustang & Fords Magazine as they go through the list of the most popular component swaps happening in the world of Fordom.
Every Monday, Mustang-360 shows another female and her Mustang. Today, it's a sister act for our Mustang Girl Monday series.


A Unique Student Identifier (USI) is a reference number made up of numbers and letters that gives students access to all records of VET courses studies in Australia. Each individual USI account will be linked to the National Vocational Education and Training (VET) Data Collection. This will allow an individual to see all of their training results from all providers including all completed training units and qualifications, making it easier for students to find and collate their VET achievements into a single authenticated transcript. It will also ensure that students' VET records are not lost.
The USI will be is available online and at no cost to the student. Allocated USIs will stay with each student for life and be recorded with any nationally recognised VET course that is completed from when the USI comes into effect on 1 January 2015.


Winchester is packed with historic buildings, museums, family attractions and tranquil green spaces just waiting to be explored.
Believed to be the oldest continuously running school in the country, Winchester College boasts some illustrious alumni including Douglas Jardine, Lord Howe and Anthony Trollope.
Uncover Winchester's past at the family-friendly City Museum.
A fortified medieval gateway which served as a debtors' prison for 150 years. Read prisoners' graffiti, see the interesting collection of weights and measures and take in splendid rooftop views across Winchester.
Float through the universe with out-of-this-world digital theatre presentations in the UK's largest planetarium.
Explore Hampshire's beautiful countryside on a steam or heritage diesel train.
Visit Marwell Wildlife and get up close to the wonders of the natural world and help save them.


Xiaomi has turned up the table with the first generation of Mi Mix, a complete bezel-less phone for which everybody gone crazy at once and also grabbed the "Outstanding Industrial Design USA" award. Well the next Mi MIX 2 will take 'bezelless' to a whole new level.
The designer Philippe Starck and posted on social media could be giving us an advance look at the Xiaomi Mi MIX 2. In a concept video shared by Philippe Starck, there's barely an outline of bezel on the top three sides with a bottom bezel that looks about half as wide as that found on the Galaxy S8.
There's more, a leaked screenshots reportedly suggest that the next generation of the bezel-less display smartphone will come with a 3D facial recognition feature. A user on Chinese website Weibo, shows the head shaped outline that suggests that the company will be including a facial recognition feature on the smartphone.
The Mi Mix 2 to sport a bezel-less 6.4-inch QHD display to be to be powered by Qualcomm Snapdragon 835 SoC coupled with 6GB of RAM. In terms of optics, the smartphone is expected to come with a 19-megapixel rear camera and a 13-megapixel camera at the front. The handset is expected to house a 4500mAh battery and Android 7.1.1 is pre-installed. The fingerprint scanner is deployed on the back of the phone.